Oncology is a field of modern medicine that focuses on diagnosis, treatment, and prevention of cancer. A medical professional with a specialty in this branch of medicine is referred to as an oncologist.
Mikhail Blagosklonny makes a cut amongst the highly acclaimed Professors of Oncology. From the year 2009, he has served the Roswell Park Cancer Institute in the capacity of Professor of Oncology.
Mikhail Blagosklonny’s medical career can be traced back to the early days when he earned a medical degree in internal medicine from the First Pavlov State Medical University of St. Petersburg. He further advanced his medical qualifications by earning a doctorate from the same institution. As a professional in medical research, He also worked at New York Medical College as a Professor of Medicine. Hitherto, he had worked as a senior research scientist at the Ordway Research Institute. Visit ResearchGate to keep up to date with Mikhail’s latest work.
His research work in oncology mainly focuses on cancer treatments that avoid damage to healthy body cells. His research also lays focus on the relationship between cancer and aging, using traditional cancer medications to decelerate the process of aging.
Using Oncotarget as a medium for publishing his research works, Mikhail Blagosklonny published an article where he was able to demonstrate success in using Rapamycin to improve immunity in the elderly. The article appeared in the journal in the year 2015. The technique of using this drug is referred to as using the TOR (Target of Rapamycin) to treat aging. He is also one of the Editors In Chief of Oncotarget.
Oncotarget as a peer-reviewed medical journal focuses on publishing findings in the field of cancer research and Oncology. The journal is released weekly from the year 2010. As one of the most acclaimed peer-review medical journal, Oncotarget aims at availing much-needed research results in Oncology.
Since cancer cases have been on a steady rise over the past years, Mikhail Blagosklonny hopes that through his research work, cancer patients can access effective medication. His research is driven by passion and a sense of responsibility to cancer patients making him an asset to the science community. Follow Mikhail on Google Scholar